Related Experiment Video
Updated: Jun 29, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
RNA modification-related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single-cell sequencing analysis
Haocheng Qin1, Shu Yang2, Zhennan Feng3
1Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Abstract:
The clinical outcomes of osteosarcoma are relatively dismal. As immunotherapy has revolutionized treatment for solid tumors, exploring novel immunotherapy-related therapeutic targets for osteosarcoma is important. In this study, we aimed to establish the connection between RNA modification and immunotherapy in osteosarcoma to identify novel therapeutic targets. An RNA modification-related signature was first developed using weight gene correlation network analysis and a machine-learning algorithm, random forest. The signature's prognostic value, drug prediction, and immune characteristics were analyzed. EIF4G2 from the signature was next identified as a critical immunotherapy determinant. EIF4G2 could also promote tumor proliferation, migration, and M2 macrophage migration by single-cell sequencing analysis and in vitro validation. Our signature and EIF4G2 are expected to provide valuable insights into the clinical management of osteosarcoma.
Insights
Researchers identified a novel RNA modification signature and EIF4G2 as a key target for improving osteosarcoma immunotherapy. This discovery offers new therapeutic strategies for this challenging bone cancer.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Osteosarcoma (bone cancer) has poor clinical outcomes, necessitating novel therapeutic strategies.
- Immunotherapy has transformed solid tumor treatment, highlighting the need for new immunotherapy targets in osteosarcoma.
Purpose of the Study:
- To investigate the link between RNA modifications and immunotherapy in osteosarcoma.
- To identify novel therapeutic targets for osteosarcoma by analyzing RNA modification-related signatures.
Main Methods:
- Developed an RNA modification-related signature using weighted gene correlation network analysis and random forest machine learning.
- Analyzed the signature's prognostic value, drug prediction capabilities, and immune characteristics.
- Identified EIF4G2 as a critical immunotherapy determinant using single-cell sequencing and in vitro validation.
Main Results:
- An RNA modification-related signature was successfully established for osteosarcoma.
- EIF4G2 was identified as a key factor influencing immunotherapy response in osteosarcoma.
- EIF4G2 was found to promote tumor proliferation, migration, and M2 macrophage infiltration.
Conclusions:
- The developed signature and EIF4G2 represent promising therapeutic targets for osteosarcoma.
- These findings offer valuable insights for advancing osteosarcoma clinical management through immunotherapy.
More Related Videos
09:58Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021